Efficacy and bleeding profile of a combined oral contraceptive containing oestradiol valerate/dienogest: a pooled analysis of three studies conducted in North America and Europe

Anita Nelson, Anita L. Nelson, Susanne Parke, Dagmar Makalova, Dagmar Makalová, Marco Serrani, Santiago Palacios, Uwe Mellinger
The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception · 2013 · vol. 18(4) , pp. 264–273 · doi:10.3109/13625187.2013.780202 · PMID:23651474 · W2035273725
Other OA: closed CC0 ⤵ 5 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This pooled analysis of three trials found that the estradiol valerate/dienogest combined oral contraceptive demonstrated a Pearl Index of 0.79, indicating reliable contraceptive efficacy in women aged 18 to 50 years.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: To summarise all clinical data on the contraceptive efficacy and bleeding profile associated with an oestradiol valerate (E2V) and dienogest (DNG) [E2V/DNG] combined oral contraceptive (COC) derived from Phase III trials. METHODS: Pooled analysis of three large-scale multicentre trials conducted in healthy women who received oral E2V/DNG for 7 to 28 cycles (28-day cycles). RESULTS: A total of 2266 women were included in this analysis. Overall, 19 pregnancies occurred over 13 cycles during 880,950 days of relevant exposure (Pearl Index [PI] of 0.79; upper limit of the two-sided 95% confidence interval [CI]: 1.23). Ten pregnancies attributed to method failure came about during 871,091 days of relevant exposure (adjusted PI of 0.42; upper limit of the two-sided 95% CI: 0.77). In women aged 18 to 35 years (n = 1687), the corresponding PI and adjusted PI were 1.01 (upper limit of the two-sided 95% CI: 1.59) and 0.51 (upper limit of the two-sided 95% CI: 0.97), respectively. In the first 13 cycles of treatment, 76 to 81% of women experienced scheduled withdrawal bleeding, and 13 to 23% experienced intracyclic bleeding. CONCLUSIONS: E2V/DNG provides reliable contraceptive efficacy in women aged 18 to 50 years.

My notes (saved in your browser only)

MeSH descriptors

Contraception Contraceptives, Oral Estradiol Nandrolone Adolescent Adult Clinical Trials, Phase III as Topic Contraception Contraceptives, Oral Drug Combinations Estradiol Estradiol Estradiol Europe Female Humans Menstruation Menstruation Metrorrhagia Metrorrhagia

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (34)

Cited by (3)

Source provenance

openalex
last seen: 2026-05-10T10:39:02.312044+00:00
pubmed
last seen: 2026-10-08T21:11:51.557491+00:00
unpaywall
last seen: 2026-10-10T06:25:47.132674+00:00
License: CC0 · commercial use OK